Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Core Viewpoint - Citius Oncology has engaged Jefferies LLC as its exclusive financial advisor to explore strategic alternatives aimed at maximizing shareholder value [1][2][3] Group 1: Strategic Engagement - The engagement with Jefferies highlights Citius Oncology's commitment to enhancing its strategic positioning and improving patient outcomes in oncology [2] - Potential strategic alternatives include partnerships, joint ventures, mergers, acquisitions, licensing, or other strategic transactions [2][3] Group 2: Product Development - Citius Oncology is preparing to launch its first cancer therapy, LYMPHIR™, which has been approved by the FDA for treating relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) [3][6] - LYMPHIR is a targeted immune therapy that specifically binds to IL-2 receptors, leading to cell death in IL-2R-expressing tumors [5] - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies [7] Group 3: Company Overview - Citius Oncology is a majority-owned subsidiary of Citius Pharmaceuticals, which focuses on developing and commercializing novel targeted oncology therapies [1][8] - Citius Pharmaceuticals also has a late-stage pipeline that includes Mino-Lok® and CITI-002 (Halo-Lido) [8][9]